TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10073329
Drug: Immediate-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxybutynin 5 mg every 8 hours for 4 days
Study: 8839195
Drug: Ultra-high-dose streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high-dose streptokinase
Study: 8839195
Drug: Conventional-dose streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose streptokinase
Study: 14621759
Drug: CMV-Polyglobulin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV-Polyglobulin (2 ml/kg body weight)
Study: 14621759
Drug: Intraglobin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraglobin (15 g)
Study: 3935486
Drug: 19NT-hexoxyphenylpropionate (19NT-HPP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19NT-hexoxyphenylpropionate (19NT-HPP), 200 mg/week intramuscularly for 7 weeks
Study: 29539274
Drug: Oral regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral regimen (fluconazole 1200 mg/day plus flucytosine 100 mg/kg/day for 2 weeks)
Study: 29539274
Drug: 1-week amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week amphotericin B (1 mg/kg/day)
Study: 29539274
Drug: 2-week amphotericin
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week amphotericin B (1 mg/kg/day)
Study: 29539274
Drug: Flucytosine as
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flucytosine as partner drug with amphotericin B
Study: 30640987
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal fumigation combined with leflunomide (20 mg) and prednisone (15 mg) once per day for 6 months
Study: 30640987
Drug: Western drugs
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western drugs (leflunomide and prednisone)
Study: 25007725
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous (IV) and topical application of tranexamic acid (TXA): 1.5 g topical TXA + 1.5 g IV-TXA
Study: 25007725
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (IV-TXA): 3 g
Study: 22505603
Drug: Buprenorphine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 180 µg/m(2) with carprofen 4 mg/kg
Study: 22505603
Drug: Buprenorphine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 180 µg/m(2) with meloxicam 0.3 mg/kg
Study: 22505603
Drug: Butorphanol 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 6 mg/m(2) with carprofen 4 mg/kg
Study: 22505603
Drug: Butorphanol 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 6 mg/m(2) with meloxicam 0.3 mg/kg
Study: 16041635
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous fluid management
Study: 7751709
Drug: Pentoxifylline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (10 mg/kg/day by continuous intravenous infusion)
Study: 30350477
Drug: Dasiglucagon 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.03 mg
Study: 30350477
Drug: Dasiglucagon 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.08 mg
Study: 30350477
Drug: Dasiglucagon 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.2 mg
Study: 30350477
Drug: Commercial glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Commercial glucagon (Eli Lilly) 0.03 mg
Study: 30350477
Drug: Commercial glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Commercial glucagon (Eli Lilly) 0.08 mg
Study: 30350477
Drug: Commercial glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Commercial glucagon (Eli Lilly) 0.2 mg
Study: 30350477
Drug: Dasiglucagon 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.03 mg in hypoglycaemia
Study: 30350477
Drug: Dasiglucagon 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.08 mg in hypoglycaemia
Study: 30350477
Drug: Dasiglucagon (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon (all doses)
Study: 29223585
Drug: Concentrated beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated beetroot juice drink (BR; 55 mL)
Study: 29223585
Drug: Non-concentrated beetroot
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-concentrated beetroot juice drink (BL; 456 mL)
Study: 29223585
Drug: Solid beetroot
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid beetroot flapjack (BF; 60 g)
Study: 29223585
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink (CON; 70 mL deionised water)
Study: 17286243
Drug: Montelukast (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (0 - 0 - 10 mg)
Study: 16119601
Drug: Propofol 6
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 6 mg kg(‐1) h(‐1) in oxygen 33% and air
Study: 2179283
Drug: Metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/ZOK 50 mg once daily for 4 weeks
Study: 2179283
Drug: Metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/ZOK 50 mg daily
Study: 696981
Drug: Diazepam (Valium)
Normalized name: diazepam Oral Tablet [Valium]
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (Valium) 0.3 mg/kg
Study: 25798748
Drug: Continuous urinary
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous urinary catheterization (CC)
Study: 21145839
Drug: BI201335 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 20 mg once-daily for 14 days
Study: 21145839
Drug: BI201335 48
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 48 mg once-daily for 14 days
Study: 21145839
Drug: BI201335 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 120 mg once-daily for 14 days
Study: 21145839
Drug: BI201335 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 240 mg once-daily for 14 days
Study: 21145839
Drug: BI201335 48
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 48 mg once-daily with PegIFN/RBV for 28 days
Study: 21145839
Drug: BI201335 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 120 mg once-daily with PegIFN/RBV for 28 days
Study: 21145839
Drug: BI201335 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 240 mg once-daily with PegIFN/RBV for 28 days
Study: 16770028
Drug: Topical Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Mitomycin C (0.01%)
Study: 15511682
Drug: Zonisamide (ZNS)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (ZNS) monotherapy initiated at 2mg/kg, increased to maintenance dosage of 8.0 mg/kg (mean, 7.97 +/- 0.55 mg/kg)
Study: 15511682
Drug: Zonisamide (ZNS)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (ZNS) monotherapy
Study: 8252111
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine oestrogens, 0.625 mg daily, with cyclical oral dl-norgestrel, 0.15 mg daily
Study: 8252111
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta-oestradiol, 0.05 mg daily, with cyclical transdermal norethisterone acetate, 0.25 mg daily
Study: 3608343
Drug: Ketoprofen 100mg
Normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100mg administered at 07.00 hours
Study: 3608343
Drug: Ketoprofen 100mg
Normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100mg administered at 13.00 hours
Study: 3608343
Drug: Ketoprofen 100mg
Normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100mg administered at 19.00 hours
Study: 3608343
Drug: Ketoprofen 100mg
Normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100mg administered at 01.00 hours
Study: 29579503
Drug: Daily PIVO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PIVO blood collections
Study: 26278513
Drug: Pre-filled pen
Normalized name: Kevzara Pre-filled Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled pen (75 mg and 150 mg doses)
Study: 26278513
Drug: Pre-filled syringe
Normalized name: Eylea Pre-filled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe (75 mg and 150 mg doses)
Study: 12957251
Drug: RCT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT plus amifostine (300 mg/m² daily i.v. infusion)
Study: 11235460
Drug: Warmed arthroscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed arthroscopic irrigation solution
Study: 11235460
Drug: Room-temperature irrigation
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room-temperature irrigation solution
Study: 8878577
Drug: Clarithromycin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (8 to 12 mg/kg)
Study: 8878577
Drug: Roxithromycin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (8 to 12 mg/kg)
Study: 1521653
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) and human menopausal gonadotropins (hMG)
Study: 6380347
Drug: Pentoxifylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (600 mg by mouth daily, increased to 1200 mg daily after one month)
Study: 30612112
Drug: Metformin, 500
Normalized name: Repaglinide-Metformin, 500 mg-1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 500 mg, three times/day during 4 months + lifestyle management
Study: 30062577
Drug: Psilocybin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (10, 20, and 30 mg/70 kg)
Study: 30062577
Drug: Dextromethorphan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (400 mg/70 kg)
Study: 24206010
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (cold pack applied over abdomen and back for 10 minutes every 30 minutes during first phase of labour; cold pack over perineum for 5 minutes every 15 minutes during second phase)
Study: 20337606
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab in combination with photodynamic therapy (COMB group)
Study: 17242095
Drug: Eritoran 2
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran 2 mg
Study: 11929196
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mixed plant oil capsules for 2 months)
Study: 10403065
Drug: Rizatriptan (5HT1B/1D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (5HT1B/1D receptor agonist)
Study: 10403065
Drug: Usual migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual migraine therapy
Study: 7726322
Drug: Inositol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (12 g/day)
Study: 2383198
Drug: Prostaglandin F2
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2 alpha‐isopropylester (PGF2 alpha‐IE) 0.5 microgram, twice daily for 1 week
Study: 19887475
Drug: Vorinostat (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (800 mg)
Study: 11433046
Drug: Educational outreach
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational outreach intervention for families and physicians, including 2 meetings with a physician peer leader and feedback on previous prescribing rates. Parents received a CDC brochure on antibiotic use.
Study: 7996376
Drug: Pentoxifylline (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1600 mg/day)
Study: 3054429
Drug: Glycerol-insulin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol-insulin treatment
Study: 8147960
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin treatment
Study: 31129983
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) for nightmares delivered over 4 weeks in addition to treatment as usual (TAU)
Study: 31129983
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) for nightmares
Study: 25933201
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of rhFGF-2/HA in the intrabony defect
Study: 10789602
Drug: sustained-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release nifedipine
Study: 8450166
Drug: Clentiazem 40
Normalized name: diltiazem hydrochloride Extended Release Oral Capsule [Kentiazem]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clentiazem 40 mg/day
Study: 8450166
Drug: Clentiazem 80
Normalized name: diltiazem hydrochloride Extended Release Oral Capsule [Kentiazem]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clentiazem 80 mg/day
Study: 8450166
Drug: Clentiazem 120
Normalized name: diltiazem hydrochloride Extended Release Oral Capsule [Kentiazem]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clentiazem 120 mg/day
Study: 28110287
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose aspirin (100 mg)
Study: 19804443
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite (HDM) allergen inhalation challenge
Study: 19804443
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen (GP) allergen inhalation challenge
Study: 9323286
Drug: Single-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose prednisolone (2 mg/kg per day as a single morning dose for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Study: 9323286
Drug: Divided-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divided-dose prednisolone (2 mg/kg per day in three divided doses for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Study: 9323286
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (single-dose and divided-dose)
Study: 31391092
Drug: Yinang formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinang formulation (YNF) plus conventional therapy
Study: 28777672
Drug: Grounded khat
Normalized name: Turmeric,ground
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grounded khat leaves extract (45 g)
Study: 26952221
Drug: 0.1mg intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mg intrathecal morphine (Group I, n=22)
Study: 26952221
Drug: 0.4mg intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4mg intrathecal morphine (Group II, n=26)
Study: 21931327
Drug: Family-based behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioural treatment (FBBT)
Study: 18572432
Drug: Rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10 mg + Acetaminophen 1000 mg (RA)
Study: 18572432
Drug: Acetaminophen alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone (A)
Study: 9142805
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ; 5/25 mg/[kg x d])
Study: 28086943
Drug: Whole-grain rye
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain rye intake (170 g/day) and vigorous physical activity (3 × 45 minutes/week) for 6 months
Study: 24366918
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg weekly
Study: 21912474
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg twice daily for 2 weeks, amoxicillin 1.0 g and clarithromycin 0.5 g twice daily for 1 week
Study: 21912474
Drug: Rabeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole, amoxicillin, and clarithromycin
Study: 19138183
Drug: Oral‐B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B CrossAction (CA) used for 1 min
Study: 10975769
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 12 weeks
Study: 10975769
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 12 weeks (only patients with normal mucosa at baseline)
Study: 10975769
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks (only patients with normal mucosa at baseline)
Study: 8931749
Drug: T-activin therapy
Normalized name: Neoantigen specific TCR-T cell therapy
DrugBank: Neoantigen specific TCR-T cell therapy (DB17458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-activin therapy
Study: 1306672
Drug: Oral-B 40
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B 40 toothbrush
Study: 22009784
Drug: Medial-sided augmentation
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial-sided augmentation (MSA)
Study: 22009784
Drug: Lateral-sided augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral-sided augmentation (LSA)
Study: 16106120
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular assist device therapy
Study: 9412304
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg twice daily, for 4 weeks
Study: 2059974
Drug: Oral fluoride
Normalized name: sodium fluoride Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluoride pharmacokinetics
Study: 6131254
Drug: Solarium exposure
Normalized name: scoparium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solarium exposure (suntan treatment)
Study: 6131254
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (age and sex matched concurrent controls)
Study: 25186131
Drug: Flexible incobotulinumtoxinA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible incobotulinumtoxinA (Xeomin®) injections at intervals of 6-20 weeks, with doses of ≤ 50 U/eye for blepharospasm and 120 U or 240 U for CD.
Study: 11250995
Drug: Fenretinide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide treatment (5-year duration)
Study: 9648698
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (FP) 200 microg four times daily for 6 days
Study: 15176496
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (FP)
Study: 7978538
Drug: Inhaled beta‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta‐adrenergic agonists
Study: 2537582
Drug: Baclofen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30 mg/day for 4 weeks)
Study: 31264940
Drug: Transdiagnostic cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive-behavioral therapy (CBT) for anxiety
Study: 21205247
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator at 0.9 mg/kg
Study: 21205247
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) 100 ml
Study: 18285727
Drug: CMV IgM
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV IgM antibody
Study: 8686975
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg every 12 hours
Study: 8686975
Drug: Ofloxacin, 400
Normalized name: Ofloxacin, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin, 400 mg every 12 hours
Study: 8686975
Drug: Ofloxacin, 400
Normalized name: Ofloxacin, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin, 400 mg, plus rifampin, 300 mg every 12 hours
Study: 2051576
Drug: M1-blocker; pirenzepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M1-blocker; pirenzepine
Study: 2051576
Drug: H2-blocker; ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-blocker; ranitidine
Study: 30394006
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) supplementation (2 × 500 mg/d)
Study: 16542056
Drug: MK‐0767 (1-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐0767 (1-80 mg single doses)
Study: 16542056
Drug: MK‐0767 (0.3-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐0767 (0.3-25 mg multiple doses once daily for 14 days)
Study: 16542056
Drug: MK‐0767 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐0767 (25 mg multiple doses once daily for 14 days)
Study: 10940094
Drug: Solubilized ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solubilized ibuprofen, 400 mg
Study: 10940094
Drug: Acetaminophen, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 1000 mg
Study: 3484773
Drug: Cefadroxil, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil, 1,000 mg single‐dose
Study: 3484773
Drug: Cefadroxil, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil, 500 mg twice a day for three days
Study: 3484773
Drug: Cefadroxil, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil, 500 mg twice a day for seven days